Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Genelux said investigators began an open-label, U.S. Phase Ib trial to evaluate IV GL-ONC1 alone or with Soliris eculizumab in about 36 patients prior to surgery. Patients will receive single doses o...
